Encephaloma chemotherapy
Brain tumor chemotherapy
1.1 Primary brain tumor
The following review articles for reference:
CHANG and PRADOS.Curr.Opin.Oncol.7 (1995) :207-213
HOSLI et al, Ann.Oncol.9 (1998) :589-600
LESSER adn GROSSMAN, Cancer Treat.Rev.19 (1993) :261-281
Semin.Oncol.21 (1994) :220-235
SCHLEGEL and KRAUSENECK, Akt.Neurol.21 (1994) :39-46
1.1.1 single-agent chemotherapy:
Try nitrosourea derivatives for treatment. For example: ACNU (100mg/m2, iv1-3 minutes, every 4-6 weeks)
BCNU (80mg/m2, iv daily, consecutive 3), CCNU, MeCCNU or Wei-meng (Teniposide VM-26, Vumon300mg/m2 ,3-5 days intravenously, repeated every 3 weeks) In addition, vincristine sulfate alkali, nitrogen, DTIC, methotrexate, methyl benzyl hydrazine, hydroxyurea, cisplatin, carboplatin, temozolomide, fotemustine and so can refer to.
1.1.2 MDT
1.1.2.1 PVC
CNCU 110 (or 130) mg/m2 P.o. d1
Procarbazine 60 (or 75) mg/m2 P.o. d8-21
Vincristine sulfate 1.4mg/m2 (maximum 2mg) Po d8 +29
Repeat every 6-8 weeks
Reference: Levin ET AL, int.J.Radiat.Oncol.Biol.Phys.18 (990) :321-324
* CAIRNCROSS et.al, J.Clin.Oncol.12 (1994) :2013-2021
1.1.2.2 AVM
ACNU 90mg/m2 i.v. d1
Teniposide (Wei-Meng) 60mg/m2 i.v. d1-3
Repeat every 6-8 weeks
Reference: SCHIEGEL and KRAUSENECK, Akt.Neurlo.21 (1994) :39-46
1.1.2.3 BVM
BCNU 80mg/m2 i.v. d1-3
Teniposide (Wei-Meng) 50mg/m2 i.v. d1 +2
Repeat every 6-8 weeks
Reference: SCHIEGEL and KRAUSENECK, Akt.Neurlo.21 (1994) :39-46
1.1.2.4 ICE (recurrence of malignant glioma salvage therapy)
Different cyclic amines 750-1200mg/m2 i.v. d1-3 *
(In order to protect the urinary tract MESNA)
Carboplatin 75mg/m2 i.v. d1-3
Teniposide (Wei-Meng) 75mg/m2 i.v. d1-3
Repeated every 4 weeks
* Subject to bone marrow tolerance may be
Reference: SANSON et.al, Eur.J.Cancer 32A (1996) :2229-2235
1.1.3 the higher grade astrocytoma, or glioblastoma
(Pleomorphic glioblastoma sensitivity to chemotherapy than glioblastoma high; for low-grade astrocytoma
There are currently no specific chemotherapy regimen).
PCV, see 1.1.2.1
AVM, see 1.1.2.2
BVM, see 1.1.2.3
1.1.4 ependymal cell tumor
AVM, see 1.1.2.2
BVM, see 1.1.2.3
1.1.5 few sticks of glial cell tumor
(Chemotherapy-sensitive)
Literature Reference: BRANDES and FIORENTINO, Cancer Treat.Rev.24 (1998) :110-111
PCV, see 1.1.2.1
1.1.6 Children's Cancer
Literature Reference: COKGOR et.al, Eur.J.Cancer 34 (1998) :1910-1918
GEYER et.al, J.Clin.Oncol.12 (1994) :1607-1615
"8-in-1" see 1.1.2.1
PCV, see 1.1.2.1
1.2 originated in the embryonic tumor (medulloblastoma)
1.2.1 PCV See 1.1.2.1
1.2.2 8-in-1 program (1 day 8-drug program)
Program A Program B
(Mg/m2) (mg/m2)
Methylprednisolone 300 300
Vincristine sulfate 1.5 (maximum dose 2.0) 1.5 (maximum dose 2.0)
Procarbazine 2525
Hydroxyurea 1500 3000
Cis-platinum 60 90
Ara-C 300 300
Cyclophosphamide 300 --
Nitrogen DTIC - 150
Program A: Medulloblastoma, PNET, ependymal cell tumor
Program B: Glioblastoma
Repeat every 2-4 weeks
Reference: PENDERGRASS et.al, J.Clin.Oncol.5 (1987) :1221-1231
1.2.3 IE
Ifosfamide 1800mg/m2 i.v. d1-5
(You need to use period is satisfied the United States to protect the urinary tract)
Etoposide 100mg/m2 i.v. d1-5
References: PEARSON, Am.J.Ped.Hematol./Oncol.15 (Suppl. A) (1993) :62-66
1.3 the source of mesenchymal tumors
Adriamycin-containing programs, see 27.1.2
1.4 Primary central nervous system lymphoma
See 41.2.8
1.5 in the planting of the nervous system primary germ cell tumors
Can be considered platinum-based programs (see 22)
1.6 metastatic brain tumors:
Those outside the lesion of central and effective programs, the same sensitivity of brain metastatic lesion
Reference: TWEL VES et al.Br.j.Cancer 64 (1990) :147-150
ROSNER et al.Cancer58 (1986) :832-839
SAWAYA er al. Neurosurg. Quart.4 (1994) :140-157
